Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders
XTalks
MAY 23, 2024
For example, pediatric growth hormone deficiency (PGHD) affects approximately one in 3,500 to one in 10,000 children. Existing therapeutic options for PGHD consist of injectable formulations of recombinant human growth hormone (rhGH), administered subcutaneously either on a daily or weekly basis.
Let's personalize your content